Principal Investigator for TroVax Phase II trials to present at Cancer Immunotherapuetics and Vaccines meeting in Cambridge, Massachusetts, on 22-23 August 2006
Oxford BioMedica repirts that Robert Amato of the Genitourinary Oncology Centre, the Methodist Hospital in Houston, USA, will make a presentation on TroVax at the third annual Cancer Immunotherapeutics and Vaccines meeting in Cambridge, Massachusetts, USA on 22 August 2006 at 14:45 EST.
The presentation will include previously reported data from a Phase II trial of TroVax in renal cell carcinoma.
Amato will present, in detail, the design of the study and preliminary safety, immunological and efficacy data.
Amato is the principal investigator for an ongoing Phase II trial of TroVax in renal cell carcinoma (RCC) in approximately 25 patients.
The trial is designed to evaluate the safety and immunogenicity of TroVax in conjunction with low dose interleukin-2, which is commonly used in the treatment of RCC.
Initial results from this Phase II trial were presented at the American Society of Clinical Oncology meeting in June 2006, confirming that TroVax is safe and well tolerated with early indications of significant tumour responses.
Dr Amato is an internationally recognised opinion leader in the treatment of RCC.
He is the principal investigator for three of the five ongoing Phase II trials of TroVax in RCC and also the Phase II trial of TroVax in prostate cancer.
Oxford BioMedica expects to commence patient recruitment in its Phase III trial in RCC, designated as Trist (TroVax renal immunotherapy survival trial), during the second half of 2006.
Oxford BioMedica has a Special Protocol Assessment agreement from the US Food and Drug Administration for the Trist study.
Further trials are also planned in colorectal cancer and other cancer types.
